Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.76 |
| ▸ | BRD4 | O60885 | 7/20 | 0.76 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.76 |
| ▸ | PLK3 | Q9H4B4 | 7/20 | 0.75 |
| ▸ | PLK2 | Q9NYY3 | 5/20 | 0.75 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.74 |
| ▸ | CLK2 | P49760 | 3/20 | 0.74 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.74 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.74 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.74 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.74 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.74 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.74 |
| ▸ | PRKCG | P05129 | 2/20 | 0.74 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.74 |
| ▸ | NEK4 | P51957 | 2/20 | 0.74 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.74 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.72 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27361479 | 0.91 | PLK1 (0.77) | PLK1BRD4ALKPLK3PLK2 | |
| SCHEMBL27361191 | 0.91 | PLK1 (0.77) | PLK1BRD4ALKPLK3PLK2 | |
| SCHEMBL25030053 | 0.91 | PLK1 (0.77) | PLK1BRD4ALKPLK3PLK2 | |
| SCHEMBL27367271 | 0.90 | PLK1 (0.76) | PLK1BRD4ALKPLK3PLK2 | |
| SCHEMBL375828 | 0.90 | PLK1 (0.77) | PLK1BRD4ALKPLK3PLK2 | |
| SCHEMBL27369567 | 0.90 | PLK1 (0.76) | PLK1BRD4ALKPLK3PLK2 | |
| SCHEMBL25784013 | 0.89 | PLK1 (0.73) | PLK1BRD4ALKPLK3PLK2 | |
| SCHEMBL13104998 | 0.89 | BRD4 (0.72) | PLK1BRD4ALKPLK3PLK2 | |
| SCHEMBL27361581 | 0.89 | PLK1 (0.74) | PLK1BRD4ALKPLK3PLK2 | |
| SCHEMBL27361297 | 0.89 | PLK1 (0.74) | PLK1BRD4ALKPLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-7807831-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7807831-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7723517-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-7723517-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-7700769-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7700769-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7629460-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-08 | — | — | US | disclosed |
| US-7629460-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-08 | — | — | US | disclosed |
| US-7547780-B2 | Cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent; leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases, arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-20080319193-A1 | New dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080319193-A1 | New dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| US-7414053-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-19 | — | — | US | disclosed |
| US-7414053-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-19 | — | — | US | disclosed |
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | GRAUERT MATTHIAS | 2008-08-14 | — | — | US | disclosed |
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | GRAUERT MATTHIAS | 2008-08-14 | — | — | US | disclosed |
| US-20080113992-A1 | Dihydropteridione Intermediate Compounds | GRAUERT MATTHIAS | 2008-05-15 | — | — | US | disclosed |
| US-20080113992-A1 | Dihydropteridione Intermediate Compounds | GRAUERT MATTHIAS | 2008-05-15 | — | — | US | disclosed |
| US-7332491-B2 | cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent: leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases: arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7332491-B2 | cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent: leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases: arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113992-A1 | Dihydropteridione Intermediate Compounds | QDPR, DHPS, DHODH | PLK1 4155/4885BRD4 4385/4885ALK 3560/4885 |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | PLK1 733/4885BRD4 1230/4885ALK 1969/4885 |
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | CCNK, CDK1, PLK1 | PLK1 3/4885BRD4 2309/4885ALK 2974/4885 |
| US-20080319193-A1 | New dihydropteridione derivatives, process for their manufacture and their use as medicament | QDPR, DHPS, DHCR7 | PLK1 4192/4885BRD4 4130/4885ALK 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.